4basebio Plc - Director/PDMR Shareholding

PR Newswire

London, December 13

13 December 2021

4basebio plc
(the "Company")
Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that, on 13 December 2021, Heikki Lanckriet, chief executive officer, acquired 3,000 ordinary shares at an average price of 652 pence per share.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,246,453 ordinary shares representing 10.12 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio plc                +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

  1. Details of the person discharging managerial responsibilities/person closely associated
  1. Name                                      Heikki Lanckriet
  1. Reason for notification
  1. Position/Status                      Chief Executive Officer
  1. Initial notification/ Amendment          Initial
  1. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  1. Name                                       4basebio plc
  1. LEI                                           213800E2DX9EAIUNCB30
  1. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
  1. Description of the financial instrument, type Ordinary Shares of instrument

    Identification Code               ISIN: GB00BMCLYF79
     
  2. Nature of the transaction    Acquisition of ordinary shares
     
  3. Price(s) and volume(s)    Volume(s)           Price (p)
     

3,000 652p

  1. Aggregated information  

    - Aggregated Volume            3,000
    - Price                                      652 pence per share
     
  2. Date of the transaction        13/12/2021
     
  3. Place of the transaction London Stock Exchange, AIM